| Pair Name | Usnic acid, Sorafenib | ||
| Phytochemical Name | Usnic acid (PubChem CID: 5646 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Usnic acid, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Down-regulation | Expression | MAP2K3 | hsa5606 |
| Down-regulation | Expression | MAPK1 | hsa5594 | |
| Down-regulation | Expression | MAPK3 | hsa5595 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| SNU-449 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0454 | |
| Result | Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid | |||
| No. | Title | Href |
|---|---|---|
| 1 | Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid. J Pharm Pharmacol. 2019 Jul;71(7):1119-1132. doi: 10.1111/jphp.13097. | Click |
